scholarly journals Patterns of Care in the Utilization of Adjuvant Radiation for Stage I Endometrial Cancer Patients Without Lymph Node Staging: A Surveillance, Epidemiology, and End Results (SEER) and Medicare Linked Analysis

2017 ◽  
Vol 99 (2) ◽  
pp. E283
Author(s):  
P.J. Boimel ◽  
C.A. Schonewolf ◽  
C.M. Brensinger ◽  
Q. Liu ◽  
E.M. Ko ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Lymph Node ◽  
Cancer Patients ◽  
Stage I ◽  
Patterns Of Care ◽  
Lymph Node Staging ◽  
Adjuvant Radiation ◽  
End Results

The effect of introducing pelvic lymphadenectomy on survival and recurrence rates in Danish endometrial cancer patients at high risk: a Danish Gynecological Cancer Group study

2019 ◽  
Vol 29 (1) ◽  
pp. 68-76 ◽  
Author(s):  
Gitte Ørtoft ◽  
Claus Høgdall ◽  
Caroline Juhl ◽  
Lone K Petersen ◽  
Estrid S Hansen ◽  
...  
Keyword(s):  
Overall Survival ◽  
Endometrial Cancer ◽  
Lymph Node ◽  
High Risk ◽  
Cancer Patients ◽  
Gynecological Cancer ◽  
Stage I ◽  
Cancer Specific Survival ◽  
High Risk Patients ◽  
Risk Patients

ObjectivesTo evaluate the rate of survival and recurrence related to the introduction of pelvic lymphadenectomy in Danish high-risk endometrial cancer patients.Study designData on 713 high-risk patients defined as grade 3 with >50% myometrial invasion or serous/clear/undifferentiated carcinomas stage I–IV endometrial cancer patients diagnosed from 2005 to 2012 were retrieved from the Danish Gynecological Cancer Database. Of these, 305 were high-risk stage I. Five year Kaplan-Meier survival estimates and actuarial recurrence rates were calculated, and adjusted Cox used for comparison. Findings were compared with earlier Danish results.ResultsLymphadenectomy in 390 radically operated high-risk patients resulted in upstaging of 31 patients from stage I to IIIC and 19 patients from stage II to IIIC corresponding to 12.8%. Upstaging from stage I to IIIC had a cancer-specific survival of 77%, almost comparable to lymph node-negative high-risk stage I patients (81%). Lymphadenectomy patients had a significant higher overall survival as compared with non-lymph node resected for all patients, but not for stage I patients. Lymphadenectomy, however, did not significantly affect cancer-specific survival, progression-free survival, recurrence rate or risk of local, distant, or lymph node recurrence. When the survival of high-risk stage I patients was compared with earlier Danish results, a small improvement in overall survival (7%) and cancer-specificsurvival (8%) was demonstrated.ConclusionOnly a small number of high-risk patients were upstaged from stage I to III due to lymphadenectomy. These patients showed a surprisingly good survival possibly due to correct stage identification and subsequent relevant adjuvant therapy. However, even though introduction of lymphadenectomy in the Danish high-risk population seems to increase overall survival, no significant change in cancer-specific survival, progression-free survival or recurrence patterns was demonstrated.

scholarly journals The role of adjuvant chemotherapy in stage I–III male breast cancer: a SEER-based analysis

2020 ◽  
Vol 12 ◽  
pp. 175883592095835
Author(s):  
Wei-Ping Li ◽  
Hong-Fei Gao ◽  
Fei Ji ◽  
Teng Zhu ◽  
Min-Yi Cheng ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Adjuvant Chemotherapy ◽  
Cancer Patients ◽  
Male Breast Cancer ◽  
Tumour Size ◽  
Male Breast ◽  
Stage I ◽  
Breast Cancer Patients ◽  
Chemotherapy Group

Background and aims: Male breast cancer is an uncommon disease. The benefit of adjuvant chemotherapy in the treatment of male breast cancer patients has not been determined. The aim of this study was to explore the value of adjuvant chemotherapy in men with stage I–III breast cancer, and we hypothesized that some male patients may safely skip adjuvant chemotherapy. Methods: Male breast cancer patients between 2010 and 2015 from the Surveillance Epidemiology and End Results database were included. Univariate and multivariate Cox analyses were used to analyse the factors associated with survival. The propensity score matching method was adopted to balance baseline characteristics. Kaplan–Meier curves were used to evaluate the impacts of adjuvant chemotherapy on survival. The primary endpoint was survival. Results: We enrolled 514 patients for this study, including 257 patients treated with chemotherapy and 257 patients without. There was a significant difference in overall survival (OS) but not in breast cancer-specific survival (BCSS) between the two groups ( p < 0.001 for OS and p = 0.128 for BCSS, respectively). Compared with the non-chemotherapy group, the chemotherapy group had a higher 4-year OS rate (97.5% versus 95.2%, p < 0.001), while 4-year BCSS was similar (98% versus 98.8%, p = 0.128). The chemotherapy group had longer OS than the non-chemotherapy group among HR+, HER2–, tumour size >2 cm, lymph node-positive male breast cancer patients ( p < 0.05). Regardless of tumour size, there were no differences in OS or BCSS between the chemotherapy and non-chemotherapy cohorts for lymph node-negative patients (OS: p > 0.05, BCSS: p > 0.05). Adjuvant chemotherapy showed no significant effects on both OS and BCSS in patients with stage I (OS: p = 0.100, BCSS: p = 0.858) and stage IIA breast cancer (OS: p > 0.05, BCSS: p > 0.05). Conclusion: For stage I and stage IIA patients, adjuvant chemotherapy could not improve OS and BCSS. Therefore, adjuvant chemotherapy might be skipped for stage I and stage IIA male breast cancer patients.

PO-1111: Pathological lymph node staging for intermediate-risk rectal cancer patients

2020 ◽  
Vol 152 ◽  
pp. S587
Author(s):  
A. Biche ◽  
A. Choudhury ◽  
L. Wee ◽  
A. Dekker ◽  
J. Van Soest ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Lymph Node ◽  
Cancer Patients ◽  
Lymph Node Staging ◽  
Intermediate Risk

Sentinel lymph node mapping detection and recurrence rates in clinical stage I endometrial cancer

2021 ◽  
Vol 162 ◽  
pp. S272
Author(s):  
Sarah Werner ◽  
Therese Gadomski ◽  
Jeannine Villella ◽  
Elena Pereira
Keyword(s):  
Endometrial Cancer ◽  
Lymph Node ◽  
Sentinel Lymph Node ◽  
Clinical Stage ◽  
Sentinel Lymph Node Mapping ◽  
Stage I ◽  
Recurrence Rates ◽  
Lymph Node Mapping

One-step nucleic acid amplification vs ultrastaging in the detection of sentinel lymph node metastasis in endometrial cancer patients

2018 ◽  
Vol 119 (3) ◽  
pp. 361-369 ◽  
Author(s):  
Jan Kosťun ◽  
Martin Pešta ◽  
Jiří Sláma ◽  
Robert Slunéčko ◽  
Pavel Vlasák ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Lymph Node ◽  
Nucleic Acid ◽  
Sentinel Lymph Node ◽  
Lymph Node Metastasis ◽  
Cancer Patients ◽  
Nucleic Acid Amplification ◽  
Sentinel Lymph Node Metastasis ◽  
Node Metastasis ◽  
One Step
Sign in / Sign up

Export Citation Format

Share Document